Tag: DBV Technologies
Private Law Firm to Investigate Claims on Behalf of Investors in...
It is unknown how this development will affect the ability of the company to eventually offer Viaskin Peanut as an FDA approved therapy.
FDA Issues Partial Hold on DBV Viaskin Peanut Patch Trial
Another delay for the long-awaited therapy.
DBV Begins Phase 3 Study of Redesigned Viaskin Peanut Patch in...
Viaskin is testing a new version of their patch designed to address the FDA's concerns.
DBV Announces Positive Topline Results from Phase 3 Trial of Viaskin...
Viaskin Peanut demonstrated a statistically significant treatment effect with 67.0% of subjects meeting the treatment responder criteria after 12 months.
Safety of Viaskin Peanut Patch Therapy Improved Over 3-Year Study
Reactions decreased over study duration.
FDA Wants More Viaskin Peanut Data Resulting in Further Approval Delays
Delays mount pushing trials of modified patch.
New Microneedle Patch Therapy for Food Allergies Takes Step Forward
Painless microneedle patch may provide new method for desensitization.
DBV Optimistic Viaskin Peanut “Patch” Therapy has Path to Approval After...
DBV, which also has Viaskin therapies for milk and egg allergies in their pipeline, is encouraged by FDA feedback after denial of their peanut therapy.
DBV, Developers of Patch Therapies for Allergies to Peanuts, Milk and...
The company announced they would be laying off 200 employees in Q1.
Viaskin Peanut “Patch” Therapy Takes Next Step Toward Approval… in Europe
The Marketing Authorization Application for Viaskin™ Peanut was validated by the European Medicines Agency.
